Endocrine Abstracts

Low testosterone is associated with an increased prevalence of cardiovascular (CV) disease. Testosterone replacement improves several CV risk factors including lowering cholesterol and may protect against atherogenesis. Macrophage liver X receptor α (LXRα) stimulates cholesterol efflux which is a therapeutic target for the treatment of atherosclerosis. It was therefore proposed that the anti-atherogenic effect of testosterone may be mediated via LXRα. THP-1 macr...

Low testosterone is associated with an increased prevalence of cardiovascular (CV) diseases such as atherosclerosis. Testosterone replacement improves several CV risk factors including lowering cholesterol. Liver X receptor α (LXRα) is present in various cell types such as macrophages where it stimulates cholesterol efflux and this ability means LXRα agonists are a potential therapy for atherosclerosis. It was therefore proposed that testosterone acts to reduce ...

Background: There is no published guidance on when to request a pituitary MRI in hypogonadal men. The presence of low or low normal gonadotrophins is common in men with symptomatic testosterone deficiency and metabolic syndrome and/or type 2 diabetes. Our practise is to perform pituitary MRI scans in men with isolated hypogonadotrophic hypogonadism who have LH< 4 Iu/l.Method: One hundred and eighty-one patients that had a pituitary MRI scan between J...

A 52-year-old woman presented in 1998 at age 26 with hirsutism, obesity, and purple striae. She had history of learning difficulties and hyperphagia since age7. Physical examination revealed a supraclavicular pad of fat and hypertension. Biochemical analysis indicated a non-suppressed low-dose dexamethasone suppression test and an ACTH level of 55 ng/l, with all other pituitary hormones normal. MRI findings showed a midline hypodense area anterior to the posterior lobe, with d...

The objective of the study was to assess the effect of intra-muscular testosterone on constitutional symptoms, sexual symptoms, memory and in men with hypogonadism and poorly-controlled type-2 diabetes. This is a randomised double-blinded placebo-controlled add-on trial of intramuscular testosterone undecanoate(Nebido®) administered every 12 weeks in 65 hypogonadal men with poorly-controlled diabetes. Phase-1 patients were randomly assigned to either treatment ...

Insulin autoimmune syndrome (Hirata syndrome) is a rare cause of hypoglycaemia. It was described by Hirata in 1970 and characterised as spontaneous hypoglycaemia, with elevated insulin levels, and associated high titres of insulin autoantibodies. It is most commonly reported in Japan and is associated with autoimmune disease or exposure to sulfhydryl-containing drugs.Continuous glucose monitoring (CGM) devices measure interstitial glucose and were initia...

Background: Low testosterone in men is associated with increase in all-cause and cardiovascular mortality. There is a high prevalence of hypogonadism in men with type 2 diabetes and testosterone replacement therapy (TRT) improves cardiovascular risk. However there is no published data regarding mortality in these patients in relation to testosterone levels, and the long term effect of TRT on mortality.Aim: We report a 6 year follow-up study examining the...

Hypogonadism is a common finding in men with metabolic syndrome (MS) and/or type 2 diabetes (T2D) which adversely affects quality of life, is associated with several cardiovascular (CV) risk factors and a greater risk of mortality. Testosterone replacement therapy (TRT) in pilot studies has beneficial effects on waist circumference (WC), insulin resistance, glycaemic control, lipid and inflammatory profiles.Testosterone replacement in hypogonadal metabol...

Background: In men with type 2 diabetes there is high prevalence of low levels of testosterone. There is accumulating evidence that low testosterone levels are associated with greater morbidity and mortality. There is no published data regarding mortality among men with type 2 diabetes in relation to testosterone levels.Aim: We report preliminary findings from our 4 to 7 years follow up study to examine the effect of baseline testosterone on all cause mo...

The objective of the study was to assess the effect of intra-muscular testosterone on glycemic control, metabolic parameters and hypogonadal symptoms in men with hypogonadism and poorly controlled type 2 diabetes. This is a randomised double-blinded placebo-controlled add-on trial of intramuscular-testosterone undecanoate(Nebido®) administered every 12 weeks in 65 hypogonadal men with poorly-controlled diabetes. Phase-1 patients were randomly assigned to either...